Work

Abstract PR-10: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.pancreatic24-pr-10

Authors: Mark H O'Hara, Max Wattenberg, Ignacio Garrido-Laguna, Eileen M O'Reilly, Michael Yellin, Tibor Keler, Michele Gargano, Nick Niles, Jeremy Drees, Nandita Bose, Gregory L Beatty

Institutions: University of Pennsylvania, University of Utah, Memorial Sloan Kettering Cancer Center, Celldex Therapeutics (United States), HiberCell, Inc. (United States)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4402551593

Cites:

Cited by: 1

Related to: 10